ES2734876T3 - Neprilisina como marcador pronóstico de insuficiencia cardiaca - Google Patents

Neprilisina como marcador pronóstico de insuficiencia cardiaca Download PDF

Info

Publication number
ES2734876T3
ES2734876T3 ES15750737T ES15750737T ES2734876T3 ES 2734876 T3 ES2734876 T3 ES 2734876T3 ES 15750737 T ES15750737 T ES 15750737T ES 15750737 T ES15750737 T ES 15750737T ES 2734876 T3 ES2734876 T3 ES 2734876T3
Authority
ES
Spain
Prior art keywords
nep
soluble
heart failure
vitro method
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15750737T
Other languages
English (en)
Spanish (es)
Inventor
Genis Antoni Bayes
Roses Josep Lupon
Ortega Amparo Galan
Martinez De Osaba Jaume Barallat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Original Assignee
Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP filed Critical Fundacio Institut dInvestigacio en Ciencies de la Salut Germans Trias i Pujol IGTP
Application granted granted Critical
Publication of ES2734876T3 publication Critical patent/ES2734876T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96497—Enkephalinase (3.4.24.11)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
ES15750737T 2014-08-29 2015-08-14 Neprilisina como marcador pronóstico de insuficiencia cardiaca Active ES2734876T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14182846.7A EP2990800A1 (en) 2014-08-29 2014-08-29 Neprilysin as heartfailure (HF) prognostic marker
PCT/EP2015/068729 WO2016030209A1 (en) 2014-08-29 2015-08-14 Neprilysin as heart failure prognostic marker

Publications (1)

Publication Number Publication Date
ES2734876T3 true ES2734876T3 (es) 2019-12-12

Family

ID=51421966

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15750737T Active ES2734876T3 (es) 2014-08-29 2015-08-14 Neprilisina como marcador pronóstico de insuficiencia cardiaca

Country Status (11)

Country Link
US (1) US10203341B2 (https=)
EP (2) EP2990800A1 (https=)
JP (1) JP6661216B2 (https=)
CN (1) CN107076758B (https=)
AU (1) AU2015309112A1 (https=)
CA (1) CA2959094A1 (https=)
ES (1) ES2734876T3 (https=)
MX (1) MX2017002453A (https=)
RU (1) RU2017109086A (https=)
SG (1) SG11201701393YA (https=)
WO (1) WO2016030209A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7510649B2 (ja) 2019-11-06 2024-07-04 国立大学法人 香川大学 心不全マーカー

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565994A (en) * 2001-09-03 2010-02-26 Intreat Pty Ltd Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions
AU2010315008B2 (en) * 2009-11-07 2015-12-03 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2360280A1 (en) * 2010-02-24 2011-08-24 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Genetic marker for the diagnosis of dementia with Lewy bodies
WO2012106152A1 (en) * 2011-02-03 2012-08-09 Abbott Laboratories Methods of prognosis and diagnosis in chronic heart failure
EP2836841B1 (en) * 2012-04-12 2022-01-05 B.R.A.H.M.S GmbH Prognosis of adverse events in patients with suspected chronic heart failure
ES2879550T3 (es) * 2012-08-24 2021-11-22 Novartis Ag Inhibidores de epn para tratar enfermedades caracterizadas por la dilatación o remodelación auriculares.
US20140206632A1 (en) 2013-01-22 2014-07-24 Singulex, Inc. Endothelin in the Diagnosis of Cardiac Disease
US9102635B2 (en) * 2013-02-14 2015-08-11 Novartis Ag Substituted bisphenyl butanoic acid derivatives as NEP inhibitors with improved in vivo efficacy
CU24330B1 (es) * 2013-02-14 2018-03-13 Novartis Ag Derivados del ácido 4-((1,1) bifenil-4-il)-3-(3-fosfonopropanamido) butanoico, activos como inhibidores de nep (endopeptidasa neutral)

Also Published As

Publication number Publication date
EP3186639B1 (en) 2019-03-20
JP6661216B2 (ja) 2020-03-11
CA2959094A1 (en) 2016-03-03
RU2017109086A3 (https=) 2019-03-06
WO2016030209A1 (en) 2016-03-03
JP2017526924A (ja) 2017-09-14
US20170254815A1 (en) 2017-09-07
US10203341B2 (en) 2019-02-12
EP2990800A1 (en) 2016-03-02
MX2017002453A (es) 2017-10-23
AU2015309112A1 (en) 2017-04-06
SG11201701393YA (en) 2017-03-30
CN107076758A (zh) 2017-08-18
RU2017109086A (ru) 2018-10-01
EP3186639A1 (en) 2017-07-05
CN107076758B (zh) 2019-10-22

Similar Documents

Publication Publication Date Title
CN105556308B (zh) 用于阑尾炎的诊断和预后及腹痛病因的区分的方法和组合物
US20200033367A1 (en) Galectin-3 immunoassay
ES2380440T3 (es) Marcador para fallo de injerto y mortalidad
ES2841739T3 (es) Método para la determinación selectiva del factor de crecimiento placental 2
ES2913539T3 (es) Identificación de pacientes con fracción de acortamiento anómala
ES2558440T3 (es) Biomarcador para el diagnóstico, predicción y/o pronóstico de insuficiencia cardiaca aguda y usos del mismo
JP2011523051A (ja) １型糖尿病におけるバイオマーカーとしてのｇｄｆ−１５
JP2015092190A (ja) 生存率予測アッセイ
ES2824110T3 (es) Troponina como marcador de fibrilación auricular intermitente
CN106716135A (zh) 心力衰竭患者的检测方法、心脏疾病的识别方法、心力衰竭的检查试剂、心力衰竭的检查试剂盒、用于检测心力衰竭的装置及用于检测心力衰竭的程序
ES2352351T3 (es) Métodos para la estratificación de la insuficiencia cardiaca.
ES2734876T3 (es) Neprilisina como marcador pronóstico de insuficiencia cardiaca
EP3311164B1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
JP2019514026A (ja) 一般集団におけるｌｖｈへの進行因子の同定のための可溶性ｓｔ２
WO2014009418A1 (en) TnT, NTproBNP, sFlt-1 for CURB65 IN PNEUMONIA
CN121532655A (zh) 用于调节免疫测定信号的方法、试剂和试剂盒
US20190250172A1 (en) Prognosis of adverse outcomes by determination of midkine levels after cardiovascular stress
HK1222454B (zh) 用於阑尾炎的诊断和预後及腹痛病因的区分的方法和组合物
WO2009150249A1 (en) Nt-probnp as prognostic indicator for the development of end stage renal disease in diabetes mellitus